Phase II clinical trial to evaluate the safety and efficacy of particle radiotherapy preceded atezolizumab plus bevacizumab treatment in patients with unresectable multiple hepatocellular carcinoma
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000048296
- Lead Sponsor
- Kobe University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 43
Not provided
1. Patients with multiple cancers. Patients with multiple cancers, but no signs of recurrence for at least 5 years after completion of treatment, and patients with epithelial cancer or endoscopically resectable gastrointestinal cancer within 5 years of completion of treatment may be enrolled. 2.Patients with untreated or poorly treated esophageal and/or gastric varices with or at high risk of bleeding. Patients who have undergone esophagogastroduodenoscopy prior to enrollment and who have been evaluated and treated for all varices, large or small, according to the institution's standard of care, and who are judged to have a low risk of bleeding may be enrolled. 3. Patients who are judged to be inappropriate to participate in this study by the principal investigator or sub-investigator. 4. Patients who are judged to be inappropriate according to the latest practice guideline for the use of atezolizumab/bevacizumab combination therapy. 5. Other patients deemed inappropriate by the study investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method Adverse event rate Tumor size reduction rate (irradiated and non-irradiated lesions) Objective response rate (RECIST) Overall survival (OS)